Enlivex receives FDA clearance for Phase 2b knee osteoarthritis trial

March 23, 2026 8:00 AM

Enlivex Ltd. (NASDAQ: ENLV) received Investigational New Drug clearance from the U.S. Food and Drug Administration to proceed with a ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

No results found